Calcineurin inhibitors in systemic lupus erythematosus

Best Practice and Research: Clinical Rheumatology

Volumn 31, Issue 3, 2017, Pages 429-438

  Mok, Chi Chiu ^a  

^a TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

Calcineurin; Cyclosporine; Lupus; Nephritis; Tacrolimus; Voclosporin

Indexed keywords

CALCINEURIN INHIBITOR; VOCLOSPORIN;

CLINICAL FEATURE; CLINICAL STUDY; COMBINATION DRUG THERAPY; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MEMBRANOUS LUPUS NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; PATHOLOGY;

CALCINEURIN INHIBITORS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 85030859140     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2017.09.010     Document Type: Review

References (82)

1. Tsokos, G.C., Systemic lupus erythematosus. N Engl J Med 365 (2011), 2110–2121.
2. Mok, C.C., Emerging biological therapies for systemic lupus erythematosus. Expert Opin Emerg Drugs 19 (2014), 303–322.
3. Katsiari, C.G., Liossis, S.N., Sfikakis, P.P., The pathophysiologic role of monocytes and macrophages in systemic lupus erythematosus: a reappraisal. Semin Arthritis Rheum 39 (2010), 491–503.
4. Fransen, J.H., van der Vlag, J., Ruben, J., et al. The role of dendritic cells in the pathogenesis of systemic lupus erythematosus. Arthritis Res Ther, 12, 2010, 207.
5. Scheinecker, C., Bonelli, M., Smolen, J.S., Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells. J Autoimmun 35 (2010), 269–275.
6. Fujio, K., Okamura, T., Sumitomo, S., et al. Regulatory cell subsets in the control of autoantibody production related to systemic autoimmunity. Ann Rheum Dis, 72(Suppl. 2), 2013 ii85-9.
7. Leffler, J., Martin, M., Gullstrand, B., et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol 188 (2012), 3522–3531.
8. Hakkim, A., Fürnrohr, B.G., Amann, K., et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A 107 (2010), 9813–9818.
9. Biermann, M.H., Veissi, S., Maueröder, C., et al. The role of dead cell clearance in the etiology and pathogenesis of systemic lupus erythematosus: dendritic cells as potential targets. Expert Rev Clin Immunol 10 (2014), 1151–1164.
10. Barbarino, J.M., Staatz, C.E., Venkataramanan, R., et al. PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics 23 (2013), 563–585.
11. Scalea, J.R., Levi, S.T., Ally, W., et al. Tacrolimus for the prevention and treatment of rejection of solid organ transplants. Expert Rev Clin Immunol 12 (2016), 333–342.
12. Yoon, K.H., Efficacy and cytokine modulating effects of tacrolimus in systemic lupus erythematosus: a review. J Biomed Biotechnol, 2010, 2010, 686480.
13. Faul, C., Donnelly, M., Merscher-Gomez, S., et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14 (2008), 931–938.
14. Liao, R., Liu, Q., Zheng, Z., et al. Tacrolimus protects podocytes from injury in lupus nephritis partly by stabilizing the cytoskeleton and inhibiting podocyte apoptosis. PLoS One, 10, 2015, e0132724.
15. Ikezumi, Y., Kanno, K., Koike, H., et al. FK506 ameliorates proteinuria and glomerular lesions induced by anti-Thy 1.1 monoclonal antibody 1-22-3. Kidney Int 61 (2002), 1339–1350.
16. Li, Y., Feng, X., Efficacy and safety of tacrolimus in systemic lupus erythematosus patients with refractory thrombocytopenia: a retrospective study. Lupus, 2017 Jan 1 961203317711011. [Epub ahead of print].
17. Li, H., Zhang, X., Chen, J., Successful treatment of steroid-refractory systemic lupus erythematosus-associated protein-losing enteropathy using combination therapy with tacrolimus and steroid. Lupus 20 (2011), 1109–1111.
18. Chighizola, C.B., Ong, V.H., Meroni, P.L., The use of cyclosporine A in rheumatology: a 2016 comprehensive review. Clin Rev Allergy Immunol 52 (2017), 401–423.
19. Ogawa, H., Kameda, H., Amano, K., et al. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus 19 (2010), 162–169.
20. Enami, T., Suzuki, T., Ito, S., et al. Successful treatment of refractory thrombotic thrombocytopenic purpura with cyclosporine and corticosteroids in a patient with systemic lupus erythematosus and antibodies to ADAMTS13. Intern Med 46 (2007), 1033–1037.
21. Wang, S.W., Cheng, T.T., Systemic lupus erythematosus with refractory hemolytic anemia effectively treated with cyclosporin A: a case report. Lupus 14 (2005), 483–485.
22. Tam, L.S., Li, E.K., Leung, C.B., et al. Long-term treatment of lupus nephritis with cyclosporin A. QJM 91 (1998), 573–580.
23. Yap, D.Y., Ma, M.K., Mok, M.M., et al. Long-term data on tacrolimus treatment in lupus nephritis. Rheumatol (Oxf) 53 (2014), 2232–2237.
24. Watanabe, H., Yamanaka, R., Sada, K.E., et al. The efficacy of add-on tacrolimus for minor flare in patients with systemic lupus erythematosus: a retrospective study. Lupus 25 (2016), 54–60.
25. Tanaka, H., Watanabe, S., Aizawa-Yashiro, T., et al. Long-term tacrolimus-based immunosuppressive treatment for young patients with lupus nephritis: a prospective study in daily clinical practice. Nephron Clin Pract 121 (2012), c165–c173.
26. Fei, Y., Wu, Q., Zhang, W., et al. Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study. Clin Exp Rheumatol 31 (2013), 62–68.
27. Suzuki, K., Kameda, H., Amano, K., et al. Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus. Rheumatol Int 31 (2011), 757–763.
28. Szeto, C.C., Kwan, B.C., Lai, F.M., et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatol (Oxf) 47 (2008), 1678–1681.
29. Mok, C.C., Tong, K.H., To, C.H., et al. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int 68 (2005), 813–817.
30. Griffiths, B., Emery, P., Ryan, V., et al. The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatol (Oxf) 49 (2010), 723–732.
31. Zavada, J., Pesickova, S., Rysava, R., et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus 19 (2010), 1281–1289.
32. Závada, J., Sinikka Pesicková S., Rysavá R., et al. Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A. Lupus 23 (2014), 69–74.
33. Chen, W., Tang, X., Liu, Q., et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis 57 (2011), 235–244.
34. Li, X., Ren, H., Zhang, Q., et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transpl 27 (2012), 1467–1472.
35. Mok, C.C., Ying, K.Y., Yim, C.W., et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis 75 (2016), 30–36.
36. Moroni, G., Doria, A., Mosca, M., et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 1 (2006), 925–932.
37. Chen, W., Liu, Q., Chen, W., et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus 21 (2012), 944–952.
38. Austin, H.A. 3rd, Illei, G.G., Braun, M.J., et al. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 20 (2009), 901–911.
39. Liu, Z., Zhang, H., Liu, Z., et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 162 (2015), 18–26.
40. Vanhove, T., Annaert, P., Kuypers, D.R., Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab Rev 48 (2016), 88–112.
41. Wiederrecht, G., Lam, E., Hung, S., et al. The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci 696 (1993), 9–19.
42. Ekberg, H., Tedesco-Silva, H., Demirbas, A., et al., ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357 (2007), 2562–2575.
43. Krämer, B.K., Del Castillo, D., Margreiter, R., et al., European Tacrolimus versus Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results. Nephrol Dial Transpl 23 (2008), 2386–2392.
44. Silva, H.T. Jr., Yang, H.C., Meier-Kriesche, H.U., et al. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. Transplantation 97 (2014), 636–641.
45. Penninga, L., Møller, C.H., Gustafsson, F., et al. Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. Eur J Clin Pharmacol 66 (2010), 1177–1187.
46. Tsujimura, S., Tanaka, Y., Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease. Clin Exp Nephrol 16 (2012), 102–108.
47. Suzuki, K., Saito, K., Tsujimura, S., et al. Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis. J Rheumatol 37 (2010), 512–520.
48. Hannah, J., Casian, A., D'Cruz, D., Tacrolimus use in lupus nephritis: a systematic review and meta-analysis. Autoimmun Rev 15 (2016), 93–101.
49. Bîrsan, T., Dambrin, C., Freitag, D.G., et al. The novel calcineurin inhibitor ISA247: a more potent immunosuppressant than cyclosporine in vitro. Transpl Int 17 (2005), 767–771.
50. Dumont, F.J., ISAtx-247 (Isotechnika/Roche). Curr Opin Investig Drugs 5 (2004), 542–550.
51. Busque, S., Cantarovich, M., Mulgaonkar, S., et al. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transpl 11 (2011), 2675–2684.
52. Dooley, M.A., Pendergraft, W. III, Ginzler, E.M., et al. Speed of remission with the use of voclosporin, MMF and low dose steroids: results of a global lupus nephritis study. [abstract] Arthritis Rheumatol, 68(suppl. 10), 2016.
53. Cortés-Hernández, J., Torres-Salido, M.T., Medrano, A.S., et al. Long-term outcomes–mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transpl 25 (2010), 3939–3948.
54. Lanata, C.M., Mahmood, T., Fine, D.M., et al. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis. Lupus 19 (2010), 935–940.
55. Mok, C.C., To, C.H., Yu, K.L., et al. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study. Lupus 22 (2013), 1135–1141.
56. Yokota, S., Mizoribine: mode of action and effects in clinical use. Pediatr Int 44 (2002), 196–198.
57. Tanaka, H., Oki, E., Tsuruga, K., et al. Mizoribine attenuates renal injury and macrophage infiltration in patients with severe lupus nephritis. Clin Rheumatol 29 (2010), 1049–1054.
58. Hara, S., Umino, D., Someya, T., et al. Protective effects of Mizoribine on Cyclosporine A nephropathy in rats. Pediatr Res 66 (2009), 524–527.
59. Nomura, A., Shimizu, H., Kishimoto, M., et al. Efficacy and safety of multitarget therapy with mizoribine and tacrolimus for systemic lupus erythematosus with or without active nephritis. Lupus 21 (2012), 1444–1449.
60. Kagawa, H., Hiromasa, T., Hara, T., et al. Mizoribine, tacrolimus, and corticosteroid combination therapy successfully induces remission in patients with lupus nephritis. Clin Exp Nephrol 16 (2012), 760–766.
61. Tanaka, H., Aizawa, T., Watanabe, S., et al. Efficacy of mizoribine-tacrolimus-based induction therapy for pediatric lupus nephritis. Lupus 23 (2014), 813–818.
62. Hallegua, D., Wallace, D.J., Metzger, A.L., et al. Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus 9 (2000), 241–251.
63. Radhakrishnan, J., Kunis, C.L., D'Agati, V., et al. Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 42 (1994), 147–154.
64. Yap, D.Y., Yu, X., Chen, X.M., et al. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrol (Carlt) 17 (2012), 352–357.
65. Bertsias, G.K., Tektonidou, M., Amoura, Z., et al., European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71 (2012), 1771–1782.
66. Mok, C.C., Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma. Nat Rev Nephrol 5 (2009), 212–220.
67. Prezzano, J.C., Beck, L.A., Long-term treatment of atopic dermatitis. Dermatol Clin 35 (2017), 335–349.
68. Kuhn, A., Ruland, V., Bonsmann, G., Cutaneous lupus erythematosus: update of therapeutic options part I. J Am Acad Dermatol 65 (2011), e179–e193.
69. Kuhn, A., Gensch, K., Haust, M., et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol 65 (2011), 54–64 64.e1-2.
70. Wang, X., Zhang, L., Luo, J., et al. Tacrolimus 0.03% ointment in labial discoid lupus erythematosus: a randomized, controlled clinical trial. J Clin Pharmacol 55 (2015), 1221–1228.
71. Barikbin, B., Givrad, S., Yousefi, M., et al. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clin Exp Dermatol 34 (2009), 776–780.
72. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm153941.htm. [Assessed 2 July 2017].
73. Mok, C.C., Pro: the use of calcineurin inhibitors in the treatment of lupus nephritis. Nephrol Dial Transpl 31 (2016), 1561–1566.
74. Fernandez Nieto, M., Jayne, D.R., Con: the use of calcineurin inhibitors in the treatment of lupus nephritis. Nephrol Dial Transpl 31 (2016), 1567–1571.
75. Kronbichler, A., Neumann, I., Mayer, G., Moderator's view: the use of calcineurin inhibitors in the treatment of lupus nephritis. Nephrol Dial Transpl 31 (2016), 1572–1576.
76. Webster, P., Wardle, A., Bramham, K., et al. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus 23 (2014), 1192–1196.
77. Bramham, K., Chusney, G., Lee, J., et al. Breastfeeding and tacrolimus: serial monitoring in breast-fed and bottle-fed infants. Clin J Am Soc Nephrol 8 (2013), 563–567.
78. Naesens, M., Kuypers, D.R., Sarwal, M., Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4 (2009), 481–508.
79. Issa, N., Kukla, A., Ibrahim, H.N., Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. Am J Nephrol 37 (2013), 602–612.
80. Staatz, C.E., Tett, S.E., Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43 (2004), 623–653.
81. Jain, S., Bicknell, G.R., Nicholson, M.L., Tacrolimus has less fibrogenic potential than cyclosporin A in a model of renal ischaemia-reperfusion injury. Br J Surg 87 (2000), 1563–1568.
82. Bao, H., Liu, Z.H., Xie, H.L., et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 19 (2008), 2001–2010.